Valneva SE (VLA.PA)
EUR 1.83
(2.93%)
EUR 1.83
(2.93%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 82.73 Million EUR | 160.37% |
| 2022 | -137.04 Million EUR | 40.92% |
| 2021 | -231.98 Million EUR | -134.47% |
| 2020 | -98.94 Million EUR | -576.21% |
| 2019 | 20.77 Million EUR | 206.63% |
| 2018 | -19.48 Million EUR | -151.34% |
| 2017 | 37.95 Million EUR | -19.66% |
| 2016 | 47.23 Million EUR | -21.73% |
| 2015 | 60.34 Million EUR | 36.23% |
| 2014 | 44.29 Million EUR | 27.39% |
| 2013 | 34.77 Million EUR | 491.18% |
| 2012 | 5.88 Million EUR | 289.07% |
| 2011 | -3.11 Million EUR | 88.87% |
| 2010 | -27.95 Million EUR | -62.71% |
| 2009 | -17.17 Million EUR | -21.96% |
| 2008 | -14.08 Million EUR | -45.1% |
| 2007 | -9.7 Million EUR | -401.18% |
| 2006 | 3.22 Million EUR | 126.81% |
| 2005 | 1.42 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 35.03 Million EUR | -57.66% |
| 2024 Q2 | 78.22 Million EUR | 123.29% |
| 2023 Q1 | -101.75 Million EUR | 25.75% |
| 2023 Q3 | 23.25 Million EUR | 142.14% |
| 2023 FY | 82.73 Million EUR | 160.37% |
| 2023 Q4 | 82.73 Million EUR | 255.85% |
| 2023 Q2 | -55.17 Million EUR | 45.77% |
| 2022 Q3 | -99.42 Million EUR | 50.94% |
| 2022 Q4 | -137.04 Million EUR | -37.84% |
| 2022 FY | -137.04 Million EUR | 40.92% |
| 2022 Q1 | -195.74 Million EUR | 15.62% |
| 2022 Q2 | -202.65 Million EUR | -3.53% |
| 2021 Q2 | -218.23 Million EUR | -68.0% |
| 2021 Q4 | -231.98 Million EUR | 0.0% |
| 2021 Q1 | -129.9 Million EUR | -31.29% |
| 2021 FY | -231.98 Million EUR | -134.47% |
| 2020 Q4 | -98.94 Million EUR | -120.31% |
| 2020 Q1 | 18.45 Million EUR | -11.17% |
| 2020 Q2 | -87.09 Million EUR | -571.9% |
| 2020 Q3 | -44.91 Million EUR | 48.44% |
| 2020 FY | -98.94 Million EUR | -576.21% |
| 2019 Q4 | 20.77 Million EUR | 26.43% |
| 2019 FY | 20.77 Million EUR | 206.63% |
| 2019 Q3 | 16.43 Million EUR | 335.57% |
| 2019 Q2 | 3.77 Million EUR | -55.3% |
| 2019 Q1 | 8.44 Million EUR | 143.32% |
| 2018 FY | -19.48 Million EUR | -151.34% |
| 2018 Q1 | 30.34 Million EUR | -20.04% |
| 2018 Q3 | 27.3 Million EUR | -0.16% |
| 2018 Q4 | -19.48 Million EUR | -171.36% |
| 2018 Q2 | 27.35 Million EUR | -9.86% |
| 2017 Q2 | 30.16 Million EUR | 0.1% |
| 2017 Q1 | 30.13 Million EUR | -36.19% |
| 2017 Q4 | 37.95 Million EUR | 29.3% |
| 2017 FY | 37.95 Million EUR | -19.66% |
| 2017 Q3 | 29.35 Million EUR | -2.71% |
| 2016 Q1 | 49.01 Million EUR | -18.77% |
| 2016 Q2 | 41.81 Million EUR | -14.7% |
| 2016 Q3 | 39.91 Million EUR | -4.55% |
| 2016 Q4 | 47.23 Million EUR | 18.35% |
| 2016 FY | 47.23 Million EUR | -21.73% |
| 2015 Q4 | 60.34 Million EUR | 18.95% |
| 2015 FY | 60.34 Million EUR | 36.23% |
| 2015 Q2 | 45.58 Million EUR | -12.12% |
| 2015 Q1 | 51.86 Million EUR | 17.09% |
| 2015 Q3 | 50.73 Million EUR | 11.31% |
| 2014 Q2 | 39.32 Million EUR | -9.83% |
| 2014 FY | 44.29 Million EUR | 27.39% |
| 2014 Q4 | 44.29 Million EUR | 7.3% |
| 2014 Q3 | 41.28 Million EUR | 4.97% |
| 2014 Q1 | 43.61 Million EUR | 25.44% |
| 2013 FY | 34.77 Million EUR | 491.18% |
| 2013 Q1 | 12.05 Million EUR | 104.98% |
| 2013 Q2 | 63.8 Million EUR | 429.19% |
| 2013 Q3 | 33.41 Million EUR | -47.63% |
| 2013 Q4 | 34.77 Million EUR | 4.06% |
| 2012 Q4 | 5.88 Million EUR | 0.0% |
| 2012 Q2 | 6.09 Million EUR | 0.0% |
| 2012 FY | 5.88 Million EUR | 289.07% |
| 2011 FY | -3.11 Million EUR | 88.87% |
| 2011 Q4 | -3.11 Million EUR | 0.0% |
| 2011 Q2 | -22.8 Million EUR | 0.0% |
| 2010 FY | -27.95 Million EUR | -62.71% |
| 2010 Q4 | -27.95 Million EUR | 0.0% |
| 2010 Q2 | -1.21 Million EUR | 0.0% |
| 2009 FY | -17.17 Million EUR | -21.96% |
| 2009 Q4 | -17.17 Million EUR | 0.0% |
| 2008 FY | -14.08 Million EUR | -45.1% |
| 2007 FY | -9.7 Million EUR | -401.18% |
| 2006 FY | 3.22 Million EUR | 126.81% |
| 2005 FY | 1.42 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | 11687.675% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 142.11% |
| Adocia SA | 127 Thousand EUR | -65046.457% |
| Aelis Farma SA | -16.19 Million EUR | 610.968% |
| Biophytis S.A. | 2.7 Million EUR | -2960.895% |
| Advicenne S.A. | 12.17 Million EUR | -579.556% |
| genOway Société anonyme | 2.97 Million EUR | -2682.942% |
| IntegraGen SA | -709.74 Thousand EUR | 11757.079% |
| Medesis Pharma S.A. | 1.15 Million EUR | -7043.437% |
| Neovacs S.A. | -237.08 Thousand EUR | 34996.894% |
| NFL Biosciences SA | -2.27 Million EUR | 3735.357% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -1799.135% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | 10061.616% |
| Sensorion SA | 1.37 Million EUR | -5903.097% |
| Theranexus Société Anonyme | 2.44 Million EUR | -3285.055% |
| TME Pharma N.V. | -1.07 Million EUR | 7767.841% |
| Valbiotis SA | -18.13 Million EUR | 556.122% |
| TheraVet SA | 12.78 Thousand EUR | -647033.359% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | -3695.229% |
| argenx SE | -1.83 Billion EUR | 104.505% |
| BioSenic S.A. | 28.04 Million EUR | -195.022% |
| Celyad Oncology SA | -6.1 Million EUR | 1455.883% |
| DBV Technologies S.A. | -114.95 Million USD | 171.972% |
| Galapagos NV | -157.2 Million EUR | 152.629% |
| Genfit S.A. | -7.61 Million EUR | 1187.058% |
| GeNeuro SA | 5.91 Million EUR | -1299.838% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | 429.468% |
| Innate Pharma S.A. | -30.71 Million EUR | 369.393% |
| Inventiva S.A. | 10.48 Million EUR | -688.788% |
| MaaT Pharma SA | -10.2 Million EUR | 910.74% |
| MedinCell S.A. | 39.5 Million EUR | -109.453% |
| Nanobiotix S.A. | -24.71 Million EUR | 434.72% |
| Onward Medical N.V. | -12.89 Million EUR | 741.663% |
| Oryzon Genomics S.A. | 1.43 Million EUR | -5684.383% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | -204.973% |
| Oxurion NV | 10.71 Million EUR | -672.512% |
| Pharming Group N.V. | 99.4 Million EUR | 16.766% |
| Poxel S.A. | 44.55 Million EUR | -85.677% |
| GenSight Biologics S.A. | 16.29 Million EUR | -407.77% |
| Transgene SA | -14.4 Million EUR | 674.197% |
| Financière de Tubize SA | 78.62 Million EUR | -5.228% |
| UCB SA | 2.17 Billion EUR | 96.2% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 546.642% |